Alkermes plc. Research and Development Expense
Alkermes plc. (ALKS) reported Research and Development Expense of $112.92 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-28.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-07-28
- Alkermes plc. research and development expense for the quarter ending 2026-06-30 was $112.92M, a 45.95% increase year-over-year.
- Alkermes plc. research and development expense for the quarter ending 2026-03-31 was $103.34M, a 43.90% increase year-over-year.
- Alkermes plc. research and development expense for the quarter ending 2025-12-31 was $93.04M, a 59.93% increase year-over-year.
- Alkermes plc. research and development expense for the quarter ending 2025-09-30 was $81.74M, a 36.48% increase year-over-year.
- Alkermes plc. research and development expense for fiscal 2025 was $323.96M, a 32.05% increase from fiscal 2024.
- Alkermes plc. research and development expense for fiscal 2024 was $245.33M, a 9.41% decline from fiscal 2023.
- Alkermes plc. research and development expense for fiscal 2023 was $270.81M, a 0.70% decline from fiscal 2022.
- Alkermes plc. research and development expense for fiscal 2022 was $272.70M, a 6.26% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $112.92M 10-Q · filed 2026-07-28 | $216.26M 10-Q · filed 2026-07-28 | $309.30M derived: sum of 3 quarters · filed 2026-07-28 | $391.04M derived: sum of 4 quarters · filed 2026-07-28 | ||||
| 2026-03-31 | $103.34M 10-Q · filed 2026-05-05 | $196.38M derived: sum of 2 quarters · filed 2026-05-05 | $278.12M derived: sum of 3 quarters · filed 2026-05-05 | $355.49M derived: sum of 4 quarters · filed 2026-07-28 | ||||
| 2025-12-31 | $93.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $174.78M derived: sum of 2 quarters · filed 2026-02-25 | $252.15M derived: sum of 3 quarters · filed 2026-07-28 | $323.96M 10-K · filed 2026-02-25 | ||||
| 2025-09-30 | $81.74M 10-Q · filed 2025-10-28 | $159.11M derived: sum of 2 quarters · filed 2026-07-28 | $230.93M 10-Q · filed 2025-10-28 | $289.10M derived: sum of 4 quarters · filed 2026-07-28 | ||||
| 2025-06-30 | $77.37M 10-Q · filed 2026-07-28 | $149.19M 10-Q · filed 2026-07-28 | $207.36M derived: sum of 3 quarters · filed 2026-07-28 | $267.25M derived: sum of 4 quarters · filed 2026-07-28 | ||||
| 2025-03-31 | $71.82M 10-Q · filed 2026-05-05 | $129.99M derived: sum of 2 quarters · filed 2026-05-05 | $189.88M derived: sum of 3 quarters · filed 2026-05-05 | $249.53M derived: sum of 4 quarters · filed 2026-05-05 | ||||
| 2024-12-31 | $58.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $118.07M derived: sum of 2 quarters · filed 2026-02-25 | $177.72M derived: sum of 3 quarters · filed 2026-02-25 | $245.33M 10-K · filed 2026-02-25 | ||||
| 2024-09-30 | $59.89M 10-Q · filed 2025-10-28 | $119.54M derived: sum of 2 quarters · filed 2025-10-28 | $187.15M 10-Q · filed 2025-10-28 | $261.08M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2024-06-30 | $59.65M 10-Q · filed 2025-07-29 | $127.26M 10-Q · filed 2025-07-29 | $201.19M derived: sum of 3 quarters · filed 2026-02-25 | $266.07M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2024-03-31 | $67.61M 10-Q · filed 2025-05-01 | $141.54M derived: sum of 2 quarters · filed 2026-02-25 | $206.42M derived: sum of 3 quarters · filed 2026-02-25 | $274.65M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2023-12-31 | $73.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $138.81M derived: sum of 2 quarters · filed 2026-02-25 | $207.04M derived: sum of 3 quarters · filed 2026-02-25 | $270.81M 10-K · filed 2026-02-25 | ||||
| 2023-09-30 | $64.88M 10-Q · filed 2024-10-24 | $97.14M 10-Q · filed 2023-10-25 | $133.10M derived: sum of 2 quarters · filed 2024-10-24 | $196.87M 10-Q · filed 2024-10-24 | $291.56M 10-Q · filed 2023-10-25 | $180.32M derived: sum of 4 quarters · filed 2025-02-12 | ||
| 2023-06-30 | $68.22M 10-Q · filed 2024-07-24 | $100.79M 10-Q · filed 2023-07-26 | $132.00M 10-Q · filed 2024-07-24 | $194.43M 10-Q · filed 2023-07-26 | $115.44M derived: sum of 3 quarters · filed 2025-02-12 | $215.87M derived: sum of 4 quarters · filed 2025-02-12 | ||
| 2023-03-31 | $63.77M 10-Q · filed 2024-05-01 | $93.64M 10-Q · filed 2023-04-26 | $47.22M derived: sum of 2 quarters · filed 2025-02-12 | $147.65M derived: sum of 3 quarters · filed 2025-02-12 | $240.52M derived: sum of 4 quarters · filed 2025-02-12 | |||
| 2022-12-31 | -$16.55M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $83.88M derived: sum of 2 quarters · filed 2025-02-12 | $176.75M derived: sum of 3 quarters · filed 2025-02-12 | $272.70M 10-K · filed 2025-02-12 | $393.84M 10-K · filed 2023-02-16 | |||
| 2022-09-30 | $100.43M 10-Q · filed 2023-10-25 | $193.30M derived: sum of 2 quarters · filed 2023-10-25 | $289.26M 10-Q · filed 2023-10-25 | $272.03M derived: sum of 4 quarters · filed 2024-02-21 | ||||
| 2022-06-30 | $92.87M 10-Q · filed 2023-07-26 | $188.83M 10-Q · filed 2023-07-26 | $171.60M derived: sum of 3 quarters · filed 2024-02-21 | $290.01M derived: sum of 4 quarters · filed 2024-02-21 | ||||
| 2022-03-31 | $95.95M 10-Q · filed 2023-04-26 | $78.72M derived: sum of 2 quarters · filed 2024-02-21 | $197.14M derived: sum of 3 quarters · filed 2024-02-21 | $294.61M derived: sum of 4 quarters · filed 2024-02-21 | ||||
| 2021-12-31 | -$17.23M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $101.18M derived: sum of 2 quarters · filed 2024-02-21 | $198.66M derived: sum of 3 quarters · filed 2024-02-21 | $290.92M 10-K · filed 2024-02-21 | $406.53M 10-K · filed 2022-02-16 | |||
| 2021-09-30 | $118.41M 10-Q · filed 2022-11-02 | $215.88M derived: sum of 2 quarters · filed 2022-11-02 | $308.15M 10-Q · filed 2022-11-02 | $420.26M derived: sum of 4 quarters · filed 2023-02-16 | ||||
| 2021-06-30 | $97.47M 10-Q · filed 2022-07-27 | $189.74M 10-Q · filed 2022-07-27 | $301.85M derived: sum of 3 quarters · filed 2023-02-16 | $396.83M derived: sum of 4 quarters · filed 2023-02-16 | ||||
| 2021-03-31 | $92.27M 10-Q · filed 2022-04-27 | $204.38M derived: sum of 2 quarters · filed 2023-02-16 | $299.36M derived: sum of 3 quarters · filed 2023-02-16 | $393.58M derived: sum of 4 quarters · filed 2023-02-16 | ||||
| 2020-12-31 | $112.11M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-16 | $207.09M derived: sum of 2 quarters · filed 2023-02-16 | $301.31M derived: sum of 3 quarters · filed 2023-02-16 | $394.59M 10-K · filed 2023-02-16 | ||||
| 2020-09-30 | $94.98M 10-Q · filed 2021-10-27 | $189.20M derived: sum of 2 quarters · filed 2021-10-27 | $282.48M 10-Q · filed 2021-10-27 | $480.64M derived: sum of 4 quarters · filed 2022-02-16 | ||||
| 2020-06-30 | $94.22M 10-Q · filed 2021-07-28 | $187.50M 10-Q · filed 2021-07-28 | $385.66M derived: sum of 3 quarters · filed 2022-02-16 | $493.33M derived: sum of 4 quarters · filed 2022-02-16 | ||||
| 2020-03-31 | $93.28M 10-Q · filed 2021-04-28 | $291.44M derived: sum of 2 quarters · filed 2022-02-16 | $399.11M derived: sum of 3 quarters · filed 2022-02-16 | $503.54M derived: sum of 4 quarters · filed 2022-02-16 | ||||
| 2019-12-31 | $198.16M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-16 | $305.83M derived: sum of 2 quarters · filed 2022-02-16 | $410.26M derived: sum of 3 quarters · filed 2022-02-16 | $512.83M 10-K · filed 2022-02-16 | ||||
| 2019-09-30 | $107.67M 10-Q · filed 2020-10-29 | $212.11M derived: sum of 2 quarters · filed 2020-10-29 | $314.68M 10-Q · filed 2020-10-29 | $423.65M derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2019-06-30 | $104.44M 10-Q · filed 2020-07-29 | $207.00M 10-Q · filed 2020-07-29 | $315.98M derived: sum of 3 quarters · filed 2021-02-11 | $417.24M derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2019-03-31 | $102.57M 10-Q · filed 2020-04-29 | $211.54M derived: sum of 2 quarters · filed 2021-02-11 | $312.81M derived: sum of 3 quarters · filed 2021-02-11 | $419.63M derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2018-12-31 | $108.97M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | $210.24M derived: sum of 2 quarters · filed 2021-02-11 | $317.06M derived: sum of 3 quarters · filed 2021-02-11 | $425.41M 10-K · filed 2021-02-11 | ||||
| 2018-09-30 | $101.27M 10-Q · filed 2019-10-23 | $208.09M derived: sum of 2 quarters · filed 2019-10-23 | $316.43M 10-Q · filed 2019-10-23 | $420.92M derived: sum of 4 quarters · filed 2020-02-13 | ||||
| 2018-06-30 | $106.82M 10-Q · filed 2019-07-25 | $215.17M 10-Q · filed 2019-07-25 | $319.66M derived: sum of 3 quarters · filed 2020-02-13 | $424.07M derived: sum of 4 quarters · filed 2020-02-13 | ||||
| 2018-03-31 | $108.35M 10-Q · filed 2019-04-25 | $212.84M derived: sum of 2 quarters · filed 2020-02-13 | $317.25M derived: sum of 3 quarters · filed 2020-02-13 | $416.40M derived: sum of 4 quarters · filed 2020-02-13 | ||||
| 2017-12-31 | $104.49M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13 | $208.90M derived: sum of 2 quarters · filed 2020-02-13 | $308.05M derived: sum of 3 quarters · filed 2020-02-13 | $412.89M 10-K · filed 2020-02-13 | ||||
| 2017-09-30 | $104.41M 10-Q · filed 2018-10-23 | $203.56M derived: sum of 2 quarters · filed 2018-10-23 | $308.40M 10-Q · filed 2018-10-23 | $398.02M derived: sum of 4 quarters · filed 2019-02-15 | ||||
| 2017-06-30 | $99.15M 10-Q · filed 2018-07-26 | $203.99M 10-Q · filed 2018-07-26 | $293.61M derived: sum of 3 quarters · filed 2019-02-15 | $393.06M derived: sum of 4 quarters · filed 2019-02-15 | ||||
| 2017-03-31 | $104.83M 10-Q · filed 2018-04-26 | $194.46M derived: sum of 2 quarters · filed 2019-02-15 | $293.90M derived: sum of 3 quarters · filed 2019-02-15 | $390.91M derived: sum of 4 quarters · filed 2019-02-15 | ||||
| 2016-12-31 | $89.63M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-15 | $189.07M derived: sum of 2 quarters · filed 2019-02-15 | $286.07M derived: sum of 3 quarters · filed 2019-02-15 | $387.15M 10-K · filed 2019-02-15 | ||||
| 2016-09-30 | $99.44M 10-Q · filed 2017-10-26 | $196.45M derived: sum of 2 quarters · filed 2017-10-26 | $297.52M 10-Q · filed 2017-10-26 | $391.21M derived: sum of 4 quarters · filed 2018-02-16 | ||||
| 2016-06-30 | $97.01M 10-Q · filed 2017-07-27 | $198.08M 10-Q · filed 2017-07-27 | $291.76M derived: sum of 3 quarters · filed 2018-02-16 | $384.32M derived: sum of 4 quarters · filed 2018-02-16 | ||||
| 2016-03-31 | $101.07M 10-Q · filed 2017-04-27 | $194.76M derived: sum of 2 quarters · filed 2018-02-16 | $287.32M derived: sum of 3 quarters · filed 2018-02-16 | $375.20M derived: sum of 4 quarters · filed 2018-02-16 | ||||
| 2015-12-31 | $93.69M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-16 | $186.24M derived: sum of 2 quarters · filed 2018-02-16 | $274.13M derived: sum of 3 quarters · filed 2018-02-16 | $344.40M 10-K · filed 2018-02-16 | ||||
| 2015-09-30 | $92.56M 10-Q · filed 2016-11-02 | $180.44M derived: sum of 2 quarters · filed 2016-11-02 | $250.72M 10-Q · filed 2016-11-02 | $325.15M derived: sum of 4 quarters · filed 2017-02-17 | ||||
| 2015-06-30 | $87.88M 10-Q · filed 2016-07-28 | $158.16M 10-Q · filed 2016-07-28 | $232.59M derived: sum of 3 quarters · filed 2017-02-17 | $310.86M derived: sum of 4 quarters · filed 2017-02-17 | ||||
| 2015-03-31 | $70.28M 10-Q · filed 2016-04-28 | $144.71M derived: sum of 2 quarters · filed 2017-02-17 | $222.97M derived: sum of 3 quarters · filed 2017-02-17 | $290.18M derived: sum of 4 quarters · filed 2017-02-17 | ||||
| 2014-12-31 | $74.43M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $152.70M derived: sum of 2 quarters · filed 2017-02-17 | $219.90M derived: sum of 3 quarters · filed 2017-02-17 | $272.04M 10-K · filed 2017-02-17 | ||||
| 2014-09-30 | $78.26M 10-Q · filed 2015-10-29 | $145.47M derived: sum of 2 quarters · filed 2015-10-29 | $197.61M 10-Q · filed 2015-10-29 | $246.33M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2014-06-30 | $67.21M 10-Q · filed 2015-07-30 | $119.35M 10-Q · filed 2015-07-30 | $168.06M derived: sum of 3 quarters · filed 2016-02-25 | $214.01M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2014-03-31 | $52.14M 10-Q · filed 2015-04-30 | $100.86M derived: sum of 2 quarters · filed 2016-02-25 | $146.80M derived: sum of 3 quarters · filed 2016-02-25 | $180.26M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2013-12-31 | $48.72M derived: 10-K 9 month − 10-Q 6 month · filed 2016-02-25 | $94.66M derived: sum of 2 quarters · filed 2016-02-25 | $128.13M 10-K · filed 2016-02-25 | $163.93M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2013-09-30 | $45.95M 10-Q · filed 2014-10-29 | $79.41M 10-Q · filed 2013-10-31 | $115.21M 10-Q · filed 2014-10-29 | $146.53M derived: sum of 4 quarters · filed 2014-10-29 | ||||
| 2013-06-30 | $33.46M 10-Q · filed 2014-07-31 | $69.26M 10-Q · filed 2014-07-31 | $100.58M derived: sum of 3 quarters · filed 2014-07-31 | $135.67M derived: sum of 4 quarters · filed 2014-07-31 | ||||
| 2013-03-31 | $35.80M 10-Q · filed 2014-04-30 | $67.12M derived: sum of 2 quarters · filed 2014-04-30 | $102.21M derived: sum of 3 quarters · filed 2014-04-30 | $140.01M 10-K · filed 2015-02-24 | ||||
| 2012-12-31 | $31.32M 10-Q · filed 2013-01-31 | $66.41M derived: sum of 2 quarters · filed 2013-10-31 | $104.21M 10-Q · filed 2013-01-31 | $149.40M derived: sum of 4 quarters · filed 2014-02-27 | ||||
| 2012-09-30 | $35.09M 10-Q · filed 2013-10-31 | $72.89M 10-Q · filed 2013-10-31 | $118.08M derived: sum of 3 quarters · filed 2014-02-27 | $158.58M derived: sum of 4 quarters · filed 2014-02-27 | ||||
| 2012-06-30 | $37.81M 10-Q · filed 2013-07-25 | $83.00M derived: sum of 2 quarters · filed 2014-02-27 | $123.49M derived: sum of 3 quarters · filed 2014-02-27 | $151.65M derived: sum of 4 quarters · filed 2014-02-27 | ||||
| 2012-03-31 | $45.19M derived: 10-KT 12 month − 10-Q 9 month · filed 2014-02-27 | $85.68M derived: sum of 2 quarters · filed 2014-02-27 | $113.84M derived: sum of 3 quarters · filed 2014-02-27 | $141.89M 10-KT · filed 2014-02-27 | ||||
| 2011-12-31 | $40.49M 10-Q · filed 2013-01-31 | $68.65M derived: sum of 2 quarters · filed 2013-01-31 | $96.70M 10-Q · filed 2013-01-31 | $124.53M derived: sum of 4 quarters · filed 2013-05-23 | ||||
| 2011-09-30 | $28.16M 10-Q · filed 2012-11-01 | $56.21M 10-Q · filed 2012-11-01 | $84.04M derived: sum of 3 quarters · filed 2013-05-23 | $106.54M derived: sum of 4 quarters · filed 2013-05-23 | ||||
| 2011-06-30 | $28.05M 10-Q · filed 2012-07-26 | $55.88M derived: sum of 2 quarters · filed 2013-05-23 | $78.38M derived: sum of 3 quarters · filed 2013-05-23 | $102.31M derived: sum of 4 quarters · filed 2013-05-23 | ||||
| 2011-03-31 | $27.83M derived: 10-K 12 month − 10-Q 9 month · filed 2013-05-23 | $50.33M derived: sum of 2 quarters · filed 2013-05-23 | $74.26M derived: sum of 3 quarters · filed 2013-05-23 | $97.24M 10-K · filed 2013-05-23 | ||||
| 2010-12-31 | $22.50M 10-Q · filed 2012-02-02 | $46.44M derived: sum of 2 quarters · filed 2012-02-02 | $69.41M 10-Q · filed 2012-02-02 | |||||
| 2010-09-30 | $23.93M 10-Q · filed 2011-11-03 | $46.91M 10-Q · filed 2011-11-03 | ||||||
| 2010-03-31 | $95.36M 10-K · filed 2012-05-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |